EVFM (Evofem Biosciences) Net Margin %: -607.90% (As of Mar. 2026)


What is Evofem Biosciences Net Margin %?

Evofem Biosciences EVFM -0.06% Net Margin % is -607.90% as of Mar. 2026. The stock has 5 warning signs investors should review. Among 947 Biotechnology companies, Evofem Biosciences ranks better than 59.66% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Evofem Biosciences's Net Income for the three months ended in Mar. 2026 was $-5.47 Mil. Evofem Biosciences's Revenue for the three months ended in Mar. 2026 was $0.90 Mil. Therefore, Evofem Biosciences's net margin for the quarter that ended in Mar. 2026 was -607.90%.

The historical rank and industry rank for Evofem Biosciences's Net Margin % or its related term are showing as below:

EVFM' s Net Margin % Range Over the Past 10 Years
Min: -31907.85   Med: -250.65   Max: 290.81
Current: -29.8

EVFM's Net Margin % is ranked better than
59.66% of 947 companies
in the Biotechnology industry
Industry Median: -89.33 vs EVFM: -29.80

Evofem Biosciences  (OTCPK:EVFM) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Evofem Biosciences Net Margin % Related Terms

Evofem Biosciences Net Margin % Historical Data

* Premium members only.

The historical data trend for Evofem Biosciences's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evofem Biosciences Net Margin % Chart

Evofem Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,488.99 -455.53 290.81 -45.76 1.94

Evofem Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 113.14 -36.97 -31.68 29.16 -607.90

EVFM vs PTIX, ATXI, AGTX: Net Margin % Comparison

For the Biotechnology subindustry, Evofem Biosciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evofem Biosciences Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Net Margin % distribution charts can be found below:

* The bar in red indicates where Evofem Biosciences's Net Margin % falls into.


Evofem Biosciences Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Evofem Biosciences's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=0.391/20.183
=1.94 %

Evofem Biosciences's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-5.465/0.899
=-607.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -607.90% mean?
Evofem Biosciences (EVFM) has a Net Margin % of -607.90% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Evofem Biosciences and its competitors. According to the industry distribution chart, Evofem Biosciences ranks #382 out of 947 companies in the Biotechnology industry, placing it in the top 40.3%.
Is Evofem Biosciences' Net Margin % too high?
Evofem Biosciences' current Net Margin % is -607.90%. Based on the distribution chart, Evofem Biosciences ranks #382 out of 947 companies in the Biotechnology industry, which is above the industry midpoint.
How does Evofem Biosciences' Net Margin % compare to PTIX and ATXI?
According to the Biotechnology industry distribution chart, Evofem Biosciences ranks #382 out of 947 companies for Net Margin %. This puts Evofem Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Evofem Biosciences and its competitors. Evofem Biosciences's current Net Margin % is -607.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evofem Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Evofem Biosciences (EVFM) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 12.8% below its estimated fair value. The current Net Margin % is -607.90%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Evofem Biosciences (EVFM), the current Net Margin % is -607.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evofem Biosciences Business Description

Address 7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.